JAMA Editors' Summary Lung Cancer Screening Benefits, Peripheral Neuropathy Review, Arsenic Exposure and Mortality, and more
11 snips
Nov 21, 2025 Explore the benefits of lung cancer screening and how increasing uptake could save lives. Discover findings from a long-term study in Bangladesh linking reduced arsenic exposure to lower chronic disease deaths. Delve into the latest insights on managing peripheral neuropathy, from conservative approaches to advanced therapies. Plus, hear about the impact of AI in clinical settings and the importance of addressing issues like third-hand smoke and innovative payment models.
AI Snips
Chapters
Transcript
Episode notes
Arsenic Reduction Lowers Mortality Risk
- Reductions in arsenic exposure were linked to substantially lower chronic disease mortality in a long-term cohort.
- Each interquartile decrease in urinary arsenic associated with ~20–23% lower mortality for chronic disease, cancer, and cardiovascular disease.
Major Life-Years Gain From Full Lung Screening
- Only a small fraction of eligible U.S. adults receive lung cancer screening despite guideline recommendations.
- Increasing screening uptake to 100% could triple life years gained and prevent a large number of deaths compared with current 18% uptake.
Policy Changes Carry Clinical Nuances
- Policy and testing changes can have nuanced clinical consequences that matter for care.
- Direct-to-test simplification and third-hand smoke disclosure laws require careful implementation to avoid treatment or disclosure pitfalls.